Drug Trial Radar · NCT00988429
Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures
Last checked: Nov 20, 2026Latest source record: May 19, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
653
Actual
Start
Dec 2, 2008
Primary completion
Jan 12, 2012
Study completion Jan 12, 2012
Sponsor
- Lead sponsor
- Bial - Portela C S.A.Industry
- Sponsor type
- Industry
- Collaborators
- Sumitomo Pharma America, Inc.
- First posted
- Oct 2, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether Eslicarbazepine acetate (BIA 2-093) is an effective adjunct therapy in the treatment of refractory partial seizures
Conditions
- Partial Epilepsy
Interventions
800 mg QD Eslicarbazepine acetateDrug
Oral, 800 mg QD, 2-week titration period and 12-week maintenance period
1200 mg QD Eslicarbazepine acetateDrug
Oral, 1200 mg QD, 2-week titration followed by 12-week maintenance period
PlaceboDrug
Placebo tablet given QD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Seizure Frequency Over the 12-week Maintenance Period.Time frame: 12-week maintenance period (Week 3 to week 14)
Locations
162 sites in 11 countries. Site status is shown where the registry gives one.
University of South Alabama Department of Neurology
Mobile, Alabama
Neurology Clinic, P.C.
Northport, Alabama
21st Century Neurology - Division of Xenoscience, Inc.
Phoenix, Arizona
Barrow Neurological Institute / St. Joseph's Hospital and Medical Center
Phoenix, Arizona
Phoenix Neurological Associates/Clinical Research Advantage
Phoenix, Arizona
ANI Research, PC
Sun City, Arizona
University of Arizona Health Sciences Center
Tucson, Arizona
Arkansas Neurology
Conway, Arkansas
Clinical Trials Inc.
Little Rock, Arkansas
Kern County Neurological Medical Group, INC.
Bakersfield, California
Neuro-Pain Medical Center, Inc.
Fresno, California
Loma Linda University
Loma Linda, California
Collaborative Neuroscience Network, INC
Long Beach, California
Viking Clinical Research Center
Murrieta, California
Bright Minds Institute
San Francisco, California
Milestone Clinical Research
San Jose, California
Neurosearch II, Inc.
Ventura, California
University of Colorado Health Sciences
Aurora, Colorado
Denver Health
Denver, Colorado
Bradenton Research Center
Bradenton, Florida
Optima Neurological Services, LLC
Gainesville, Florida
University of Florida Department of Neurology
Gainesville, Florida
NW FL Clinical Research Group, LLC
Gulf Breeze, Florida
Palm Springs Research Institute
Hialeah, Florida
University of Florida
Jacksonville, Florida
Pharmax Research Clinic
Miami, Florida
Advanced Pharma CR, LLC
Miami, Florida
University of Miami - Miller School of Medicine Department of Neurology
Miami, Florida
Miami Children's Hospital
Miami, Florida
Neuroscience Consultants
Miami, Florida
Kendall South Medical Center, Inc.
Miami, Florida
Medsol Clinical Research Center
Port Charlotte, Florida
Lovelace Scientific Resources
Sarasota, Florida
University of South Florida - Department of Neurology
Tampa, Florida
Pediatric Epilepsy & Neurology Specialists, PA
Tampa, Florida
Lovelace Scientific Resources
Venice, Florida
Palm Beach Clinical Research Network, LLC.
Wellington, Florida
Harbin Clinic
Rome, Georgia
Consultants in Epilepsy and Neurology, PPLC
Boise, Idaho
Southern Ilinois University School of Medicine
Springfield, Illinois
Showing 40 of 162 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.